

Special Issue

State-of-the-Art on Gastrointestinal Cancers in Italy

Message from the Guest Editors

This regional Special Issue aims to provide a wide overview of diagnostic and treatment tools available for gastrointestinal (GI) cancer patients in Italy. GI cancers, which mostly consist of colorectal, gastric, and esophageal cancer, represent the third most commonly diagnosed tumors worldwide, with a progressively growing burden, even in Italy. Novel diagnostic tools (such as biomarkers or liquid biopsy) and multimodality approaches have been reported to significantly improve the outcomes of GI cancers. We invite the submission of research articles that will consolidate our understanding in this area, with a specific focus on the state of the art in Italy. This Special Issue will publish original research and review articles. Potential topics include, but are not limited to:

- Biomarkers;
- Microbiota in the diagnosis and treatment of GI cancers;
- Liquid biopsy;
- Diagnosis and therapy of GI cancers;
- Recent advances in GI cancers therapies.

Guest Editors

Dr. Marco Vacante

Unit of Internal Medicine Critical Area—ARNAS Garibaldi, Catania, Italy

Prof. Dr. Antonio Biondi

Department of General Surgery and Surgical—Medical Specialties,
University of Catania, Catania, Italy

Deadline for manuscript submissions

closed (30 June 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/93574

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).